latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/mei-pharma-s-blood-cancer-drug-gets-us-fda-fast-track-tag-57838462 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

MEI Pharma's blood cancer drug gets US FDA fast-track tag

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

MEI Pharma's blood cancer drug gets US FDA fast-track tag

The U.S. Food and Drug Administration granted fast-track status to MEI Pharma Inc.'s drug ME-401 to treat patients with a type of blood cancer.

The designation was given to ME-401 to treat patients with relapsed or refractory follicular lymphoma that has not improved after receiving at least two prior lines of systemic therapy.

Follicular lymphoma is a type of cancer that develops when the body makes abnormal versions of white blood cells called B lymphocytes, or B cells, which help protect the body against bacteria or viruses by making proteins called antibodies.

San Diego, Calif.-based MEI Pharma is evaluating ME-401 as a stand-alone therapy in a phase 2 trial, dubbed Tidal, in patients with this indication. The company plans to use this study to support its request to the U.S. regulator for accelerated approval.

The FDA grants fast-track designation to products that can address an unmet medical need, with benefits including eligibility for a rolling submission of a drug and the possibility of an expedited review.